The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients

Christian Kuntzen; Zohaib Bagha

doi:10.1016/j.cld.2022.01.012

The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients

Clin Liver Dis. 2022 May;26(2):291-312. doi: 10.1016/j.cld.2022.01.012. Epub 2022 Apr 1.

Authors

Christian Kuntzen¹, Zohaib Bagha²

Affiliations

¹ Hofstra University at Northwell Health, 300 Community Drive, Manhasset, NY 11030, USA. Electronic address: ckuntzen@northwell.edu.
² Hofstra University at Northwell Health, 300 Community Drive, Manhasset, NY 11030, USA.

PMID: 35487612
DOI: 10.1016/j.cld.2022.01.012

Abstract

The use of hepatitis C virus (HCV) -positive organs in HCV-negative recipients with posttransplant antiviral treatment has increasingly been studied since the introduction of new direct-acting antivirals. This article reviews existing experience in liver and kidney transplant. Fifteen studies with 218 HCV D+/R- liver transplants, with 182 from viremic donors, show a sustained viral response for 12 weeks (SVR12) rate of 99.5%. Nine studies involving 204 HCV donor-positive recipient-negative kidney transplant recipients had an SVR12 rate of 99.5%. Complications are infrequent. Preemptive treatment in kidney transplant of for only 4 weeks or even 4 days showed surprising success rates.

Keywords: Donor; Fibrosing cholestatic hepatitis; HCV; Hepatitis C; Liver transplant; Negative; Positive; Recipient.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use
Hepacivirus
Hepatitis C* / complications
Hepatitis C* / drug therapy
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / drug therapy
Humans
Tissue Donors

Substances

Antiviral Agents